Illumina is widely regarded as the giant of NGS, with an estimated 80 per cent share of the global gene sequencing market. At the heart of Illumina’s nucleic acid sequencing technologies is sequencing-by-synthesis (SBS), a chemistry with a humble and fascinating backstory.
Georgia Rundle and Jian Siang Poh tell all in the second in our series for leading Cambridge publication, Business Weekly.